Case reports of ALK tyrosine kinase inhibitors used in ALK fusion positive CRC show promise477, so that diagnostic gene sequencing panels used in refractory disease should also include NTRK, ALK and other known fusion genes (e.g., ROS, RET). This evidence concerns the gene ALK and colorectal carcinoma.